SEC Form 4 · accession 0001209191-17-007627
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Feb 1, 2017
Accepted (ET)
Feb 3, 2017 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 1, 2017 | S | 400 | $85.08 | D | 112,203 | D | |
| Common StockF2,F4 | Feb 1, 2017 | S | 1,500 | $85.91 | D | 110,703 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
- F2Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $85.08 (range $84.67 to $85.44).
- F4Open market sales reported on this line occurred at a weighted average price of $85.91 (range $85.70 to $86.16).